What Docetaxel Teva concentrate vial contains:
- The active substance is docetaxel. Each vial of Docetaxel Teva concentrate contains 80 mg of docetaxel. Each ml of concentrate contains 27.73 mg docetaxel.
- The other ingredients are polysorbate 80 and 25.1% (w/w) anhydrous ethanol.
What the solvent vial contains:
Water for injections.
What Docetaxel Teva looks like and contents of the pack:
Docetaxel Teva concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution.
Each carton contains:
- one 15 ml clear glass vial with a flip-off cap containing 2.88 ml concentrate and,
- one 15 ml clear glass vial with a flip-off cap containing 5.12 ml of solvent.
Marketing Authorisation Holder
Teva Pharma B.V.
Computerweg 10
3542 DR Utrecht
The Netherlands
Manufacturer:
Pharmachemie B.V.
Swensweg 5
PO Box 552
2003 RN Haarlem, The Netherlands
TEVA Pharmaceutical Works Private Limited Company
Táncsics Mihály út 82
H-2100 Gödöll-,
Hungary
Teva Kutno SA
Sienkiewicza 25;
99-300 Kutno
Poland
Teva Czech Industries s.r.o
Ostravská 29
-.p. 305
747 70 Opava-Komárov
Czech Republic
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien Teva Pharma Belgium N.V.S.A. TelTél 32 3 820 73 73 LuxembourgLuxemburg Teva Pharma Belgium S.A. Tél 32 3 820 73 73
Te 359 2 489 95 82 Magyarország Teva Magyarország Zrt Tel. 36 1 288 64 00
eská republika Teva Pharmaceuticals CR, s.r.o. Tel 420 251 007 111 Malta Teva .. el 30 210 72 79 099
Danmark Teva Denmark AS Tlf 45 44 98 55 11 Nederland Teva Nederland B.V. Tel 31 0 800 0228400
Deutschland Teva Generics GmbH Tel 49 351 834 0 Norge Teva Sweden AB Tlf 46 42 12 11 00
Österreich Teva Generics GmbH Tel 49 351 834 0 Eesti Teva Eesti esindus UAB Sicor Biotech Eesti filiaal Tel 372 611 2409
Teva .. 30 210 72 79 099 Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel. 48 22 345 93 00
España Teva Genéricos Española, S.L.U. Tél 34 91 387 32 80 Portugal Teva Pharma - Produtos Farmacêuticos Lda Tel 351 214 235 910
France Teva Santé Tél 33 1 55 91 7800 România Teva Pharmaceuticals S.R.L Tel 4021 212 08 90
Ireland Teva Pharmaceuticals Ireland Tel 353 042 9395 892 Slovenija Pliva Ljubljana d.o.o. Tel 386 1 58 90 390
Ísland Teva UK Limited Sími 44 1323 501 111. Slovenská republika Teva Pharmaceuticals Slovakia s.r.o. Tel 421 2 5726 7911
Italia Teva Italia S.r.l. Tel 39 0289179805 SuomiFinland Teva Sweden AB PuhTel 46 42 12 11 00
Teva .. 30 210 72 79 099 Sverige Teva Sweden AB Tel 46 42 12 11 00
Latvija UAB Sicor Biotech filile Latvij Tel 371 67 784 980 United Kingdom Teva UK Limited Tel 44 1323 501 111
Lietuva
UAB ?Sicor Biotech?
Tel: +370 5 266 02 03
This leaflet was last approved in { MM/YYYY}
The following information is intended for medical or healthcare professional only:
PREPARATION GUIDE FOR USE WITH DOCETAXEL TEVA 80 mg CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION
__________________________________________________________________________
It is important that you read the entire contents of this procedure prior to the preparation of either the Docetaxel Teva premix solution or the Docetaxel Teva infusion solution
1. FORMULATION
Docetaxel Teva 80 mg concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80. The solvent for Docetaxel Teva is water for injections.
2. PRESENTATION
Docetaxel Teva is supplied as single-dose vials.
Each box contains one Docetaxel Teva vial (80 mg) and one corresponding solvent for Docetaxel Teva vial in a carton.
Docetaxel Teva vials should not be stored above 25°C and should be protected from light. Docetaxel Teva should not be used after the expiry date shown on the carton and vials.
2.1 Docetaxel 80 mg vial:
- The Docetaxel 80 mg vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
- The Docetaxel 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 27.73 mg/ml.
Each vial contains 80 mg/2.88 ml of a 27.73 mg/ml solution of docetaxel in polysorbate 80 (fill volume: 94.4 mg/3.40 ml). This fill volume has been established during the development of docetaxel to compensate for liquid loss during preparation of the premix due to foaming, adhesion to the walls of the vial and "dead-volume". This overfill ensures that after dilution with the entire contents of the accompanying solvent for docetaxel vial, there is a minimal extractable premix volume of 8 ml containing 10 mg/ml docetaxel which corresponds to the labelled amount of 80 mg per vial.
2.2 Solvent for Docetaxel 80 mg vial:
- The solvent for Docetaxel 80 mg vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
- The solvent for Docetaxel composition is water for injections.
Each solvent vial contains 5.12 ml of water for injections (fill volume: 6.29 ml). The addition of the entire contents of the solvent vial to the contents of the docetaxel 80 mg concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
3. RECOMMENDATIONS FOR THE SAFE HANDLING
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva solutions. The use of gloves is recommended.
If Docetaxel Teva concentrate, premix solution or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water. If Docetaxel Teva concentrate, premix solution or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.
4. PREPARATION FOR THE INTRAVENOUS ADMINISTRATION 4.1 Preparation of the Docetaxel Teva premix solution (10 mg docetaxel/ml)
4.1.1 If the vials are stored under refrigeration, allow the required number of Docetaxel Teva boxes
to stand at room temperature (below 25°C) for 5 minutes.
4.1.2 Using a syringe fitted with a needle, aseptically withdraw the entire contents of the solvent for
Docetaxel Teva vial by partially inverting the vial.
4.1.3 Inject the entire contents of the syringe into the corresponding Docetaxel Teva vial.
4.1.4 Remove the syringe and needle and mix manually by repeated inversions for at least 45
seconds. Do not shake.
4.1.5 Allow the premix vial to stand for 5 minutes at room temperature (below 25°C) and then
check that the solution is homogenous and clear (foaming is normal even after 5 minutes due
to the presence of polysorbate 80 in the formulation).
The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation. However the chemical and physical stability of the premix solution has been demonstrated for 8 hours when stored either between +2°C and +8°C or at room temperature (below 25°C).
4.2 Preparation of the infusion solution
4.2.1 More than one premix vial may be necessary to obtain the required dose for the patient. Based
on the required dose for the patient expressed in mg, aseptically withdraw the corresponding
premix volume containing 10 mg/ml docetaxel from the appropriate number of premix vials
using graduated syringes fitted with a needle. For example, a dose of 140 mg docetaxel would
require 14 ml docetaxel premix solution.
4.2.2 Inject the required premix volume into a 250 ml non-PVC infusion bag containing either 5%
glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. If a dose greater
than 200 mg of docetaxel is required, use a larger volume of the infusion vehicle so that a
concentration of 0.74 mg/ml docetaxel is not exceeded.
4.2.3 Mix the infusion bag or bottle manually using a rocking motion.
4.2.4 The Docetaxel Teva infusion solution should be used within 4 hours and should be aseptically
administered as a 1-hour infusion under room temperature (below 25°C) and normal lighting conditions.
4.2.5 As with all parenteral products, Docetaxel Teva premix solution and infusion solution should
be visually inspected prior to use, solutions containing a precipitate should be discarded.
5. DISPOSAL
All materials that have been utilised for dilution and administration should be disposed of according to standard procedures.